ArticleThe American journal of pathology2007
Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms.
Article in The American journal of pathology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Friend or foe: assessing the value of animal models for facilitating clinical breakthroughs in complement research.The Journal of clinical investigation · 2025Review
- CD8Nature communications · 2023Article
- Complement Decay-Accelerating Factor is a modulator of influenza A virus lung immunopathology.PLoS pathogens · 2021Article
- Beyond the Role of CD55 as a Complement Component.Immune network · 2018Review
- CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis.The New England journal of medicine · 2017Article
- Complement in Lupus Nephritis: New Perspectives.Kidney diseases (Basel, Switzerland) · 2015Review
- Decay-accelerating factor 1 deficiency exacerbates leptospiral-induced murine chronic nephritis and renal fibrosis.PloS one · 2014Article
- The role of decay accelerating factor in environmentally induced and idiopathic systemic autoimmune disease.Autoimmune diseases · 2014Review
- Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury.Circulation research · 2013Article
- Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Depletion of complement does not impact initiation of xenobiotic-induced autoimmune disease.Immunology · 2012Article
- Complement factor H deficiency accelerates development of lupus nephritis.Journal of the American Society of Nephrology : JASN · 2011Article
- Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury.The Journal of clinical investigation · 2010Article
- Decay-accelerating factor 1 (Daf1) deficiency exacerbates xenobiotic-induced autoimmunity.Immunology · 2010Article
- Role and mechanism of action of complement in regulating T cell immunity.Molecular immunology · 2010Review
- Toxicology of autoimmune diseases.Chemical research in toxicology · 2010Review
- A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis.Genes and immunity · 2010Article
- Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.Molecular immunology · 2009Article
- Uncoupling CD21 and CD19 of the B-cell coreceptor.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).Journal of proteome research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Decay-accelerating factor (DAF) is a glycosylphosphatidylinositol-anchored membrane protein that restricts complement activation on autologous cells. Previous studies have established a significant protective activity of DAF in the MRL/lpr murine model of human systemic lupus erythematosus. To dissect the mechanism of protection by DAF in this disease model, we evaluated the effect of C3 gene ablation on disease development in MRL/lpr-Daf-1(-/-) mice. We found no significant difference in lymphadenopathy, splenomegaly, or anti-chromatin autoantibody titer between complement-sufficient and complement-deficient MRL/lpr-Daf-1(-/-) mice. On the other hand, complement deficiency strikingly reduced the incidence and severity of dermatitis in MRL/lpr-Daf-1(-/-) mice. To assess the contribution of DAF expression on lymphocytes versus local tissues in suppressing dermatitis, we generated BM chimeric mice between MRL/lpr-Daf-1(-/-) and MRL/lpr-Daf-1(+/+) mice. Compared with MRL/lpr-Daf-1(-/-) --> MRL/lpr-Daf-1(-/-) controls, MRL/lpr-Daf-1(-/-) --> MRL/lpr-Daf-1(+/+) chimeras developed significantly attenuated dermatitis, suggesting that the protective effect of DAF in suppressing dermatitis is primarily attributable to its local expression. We conclude that DAF works as a complement regulator in the skin to protect MRL/lpr mice from skin inflammation, whereas its inhibitory role in the induction phase of MRL/lpr autoimmunity is complement-independent. Together, these results reveal multiple mechanisms of action for DAF in ameliorating systemic autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.